According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is HK$0.28 Billion. In 2022 the company made a revenue of -HK$0.26 Billion a decrease over the revenue in the year 2021 that were of HK$0.10 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.